Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?

Ann Palliat Med. 2022 Aug;11(8):2789-2791. doi: 10.21037/apm-22-618. Epub 2022 Jul 26.

Authors

Jian-Hao Deng¹, Guo-Wei Zhong², Jia-Xing Zhang³

Affiliations

¹ Department of Pharmacy, Longyan Second Hospital, Longyan, China.
² Department of Traditional Chinese Medicine, Longyan Second Hospital, Longyan, China.
³ Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, China.

PMID: 35948476
DOI: 10.21037/apm-22-618

No abstract available

MeSH terms

Allopurinol / therapeutic use
Febuxostat / therapeutic use
Gout Suppressants / therapeutic use
Gout* / complications
Gout* / drug therapy
Humans
Hyperuricemia* / complications
Hyperuricemia* / drug therapy
Treatment Outcome
Uric Acid

Substances

Gout Suppressants
Febuxostat
Uric Acid
Allopurinol